Growth Hormone Disorder Clinical Trial
Official title:
Effect of Growth Hormone in Children With Growth Hormone Deficiency and Idiopathic Short Stature
Verified date | January 2017 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is conducted in the United States of America (USA). The purpose of the trial is to compare the effect of Norditropin® using different dosing regimens in children suspected of growth hormone deficiency.
Status | Completed |
Enrollment | 173 |
Est. completion date | May 2004 |
Est. primary completion date | May 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 15 Years |
Eligibility |
Inclusion Criteria: - Clinically suspected GHD - Height < -2.0 SDS - Serum IGF-I less than or equal to -1.0 SDS - Bone age less than or equal to 9 years for boys and less than or equal to 7 years for girls. - Puberty Tanner Stage I Exclusion Criteria: - Previous use of growth hormone - Growth retardation attributable to causes other than GHD (e.g. inborn errors of metabolism, primary bone disease, chromosomal disorders, etc.) - Intrauterine growth retardation: birth weight < 3rd percentile. - Administration of other growth-altering medications. - Evidence of any malignancy or intracranial tumors. |
Country | Name | City | State |
---|---|---|---|
United States | Novo Nordisk Investigational Site | Baltimore | Maryland |
United States | Novo Nordisk Investigational Site | Bronx | New York |
United States | Novo Nordisk Investigational Site | Brooklyn | New York |
United States | Novo Nordisk Investigational Site | Buffalo | New York |
United States | Novo Nordisk Investigational Site | Charleston | South Carolina |
United States | Novo Nordisk Investigational Site | Cincinnati | Ohio |
United States | Novo Nordisk Investigational Site | Cleveland | Ohio |
United States | Novo Nordisk Investigational Site | Cleveland | Ohio |
United States | Novo Nordisk Investigational Site | Columbia | South Carolina |
United States | Novo Nordisk Investigational Site | Columbus | Ohio |
United States | Novo Nordisk Investigational Site | Gainesville | Florida |
United States | Novo Nordisk Investigational Site | Hershey | Pennsylvania |
United States | Novo Nordisk Investigational Site | Indianapolis | Indiana |
United States | Novo Nordisk Investigational Site | Iowa City | Iowa |
United States | Novo Nordisk Investigational Site | Kalamazoo | Michigan |
United States | Novo Nordisk Investigational Site | Kansas City | Missouri |
United States | Novo Nordisk Investigational Site | Los Angeles | California |
United States | Novo Nordisk Investigational Site | Los Angeles | California |
United States | Novo Nordisk Investigational Site | Memphis | Tennessee |
United States | Novo Nordisk Investigational Site | Milwaukee | Wisconsin |
United States | Novo Nordisk Investigational Site | Minneapolis | Minnesota |
United States | Novo Nordisk Investigational Site | Minneapolis | Minnesota |
United States | Novo Nordisk Investigational Site | Morristown | New Jersey |
United States | Novo Nordisk Investigational Site | New Haven | Connecticut |
United States | Novo Nordisk Investigational Site | New Hyde Park | New York |
United States | Novo Nordisk Investigational Site | New York | New York |
United States | Novo Nordisk Investigational Site | Philadelphia | Pennsylvania |
United States | Novo Nordisk Investigational Site | Portland | Oregon |
United States | Novo Nordisk Investigational Site | Sacramento | California |
United States | Novo Nordisk Investigational Site | San Antonio | Texas |
United States | Novo Nordisk Investigational Site | San Diego | California |
United States | Novo Nordisk Investigational Site | Seattle | Washington |
United States | Novo Nordisk Investigational Site | Shreveport | Louisiana |
United States | Novo Nordisk Investigational Site | Skokie | Illinois |
United States | Novo Nordisk Investigational Site | Springfield | Massachusetts |
United States | Novo Nordisk Investigational Site | St. Petersburg | Florida |
United States | Novo Nordisk Investigational Site | Stanford | California |
United States | Novo Nordisk Investigational Site | Stony Brook | New York |
United States | Novo Nordisk Investigational Site | Tallahassee | Florida |
United States | Novo Nordisk Investigational Site | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
United States,
Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG; American Norditropin Study Group.. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007 Jul;92(7):248 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in height standard deviation score | 24 month | ||
Secondary | IGF-I | |||
Secondary | IGFBP-3 | |||
Secondary | free IGF-I |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02229851 -
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
|
Phase 3 | |
Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
Completed |
NCT01562834 -
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
|
Phase 4 | |
Completed |
NCT01109017 -
Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency
|
N/A | |
Completed |
NCT01706783 -
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
|
Phase 1 | |
Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
Completed |
NCT00184730 -
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
|
Phase 3 | |
Completed |
NCT01502124 -
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
|
Phase 3 | |
Completed |
NCT00519558 -
Growth Hormone Deficiency in Adults (GHDA)
|
Phase 3 | |
Completed |
NCT01604161 -
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
|
N/A | |
Completed |
NCT00102817 -
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
|
Phase 3 | |
Terminated |
NCT01698944 -
Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency
|
Phase 4 | |
Completed |
NCT03075644 -
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02616562 -
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
|
Phase 2 | |
Completed |
NCT02005198 -
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
|
N/A | |
Completed |
NCT00567385 -
Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 4 | |
Completed |
NCT01009905 -
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
|
N/A | |
Completed |
NCT03186495 -
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
|
Phase 1 | |
Completed |
NCT00934063 -
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
|
N/A | |
Completed |
NCT00722540 -
Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
|
Phase 1 |